Share
Our Company

Johnson & Johnson Establishes Ethical Framework to Guide Our Decisions During the COVID-19 Pandemic

Share

Johnson & Johnson is involved in a range of efforts to help in the fight against COVID-19, including evaluating a variety of medicines for possible treatment and prevention of the virus.

Clinical trials remain the best way to understand the potential risks and benefits of a treatment. That is why we are doing all we can to expedite our clinical trials. We also understand that we are living in unprecedented times when solutions are needed urgently.

In the face of the pandemic, we remain committed to allocating our resources fairly and responsibly with the aim to save as many lives as possible.

Johnson & Johnson, in collaboration with internal and external experts, has developed an ethics-based framework for decision-making during the COVID-19 pandemic. This framework will guide how we will allocate supply of our products that we are currently studying for the treatment and prevention of COVID-19. Consistent with our Credo, the framework puts an emphasis on reducing suffering, saving the greatest number of lives, and supporting those who are working the frontlines of the pandemic.

You can read the framework here.

The framework was developed by the Johnson & Johnson’s Office of the Chief Medical Officer, or OCMO. Functionally independent from commercial interests, the OCMO takes an evidence- and science-based, ethics- and values-driven approach to medical safety across all products in the Johnson & Johnson Family of Companies. With today’s urgency in mind, our commitment to the safety of our patients and consumers remains as strong as ever. We will continue to push forward with the goal of helping as many people as possible, in the safest way possible.

For more information on accessing Janssen investigational medicines, click here to contact the local Janssen Medical Information team in your country. Healthcare professionals in the United States can contact Janssen Medical Information at 1-800-JANSSEN or email us at janssenmedinfo@its.jnj.com.

To read Janssen pre-approval access policy, click here.

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue